A placebo-controlled, dose-ranging, randomized Phase 2 study of ALPN 303 in systemic lupus erythematosus (SLE) and potentially additional autoantibody-related diseases
Latest Information Update: 26 Nov 2023
At a glance
- Drugs [90Y]Y-PentixaTher (Primary) ; Povetacicept (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Proof of concept
- Acronyms RUBY-2
- Sponsors Alpine Immune Sciences
Most Recent Events
- 15 Nov 2023 According to an Alpine Immune Sciences media release, the company plans to initiate this study in 2H 2024.
- 23 Mar 2023 According to an Alpine Immune Sciences media release, the company plans to launch this study in mid-2024, based on enabling data from the RUBY-3 and RUBY-4 studies.
- 14 Nov 2022 According to an Alpine Immune Sciences media release, the company presented broad development plan including this study at the R&D Day on Sep 2022.